New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 5, 2014
07:39 EDTADXSAdvaxis to initiate clinical development of ADXS-cHER2
Advaxis announced it intends to initiate a clinical development program with its product candidate, ADXS-cHER2, for the treatment of pediatric osteosarcoma. ADXS-cHER2 is an immunotherapy that targets the HER2 oncogene, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer and breast cancer. In a veterinarian clinical study, pet dogs with naturally occurring osteosarcoma treated with ADXS-cHER2 after the standard of care showed a statistically significant prolonged overall survival benefit compared with dogs that received standard of care without ADXS-cHER2. Both veterinary and human osteosarcoma specialists consider canine osteosarcoma to be the best model for human osteosarcoma. Building on these data, Advaxis now intends to initiate a clinical development program in pediatric patients with osteosarcoma. Pediatric osteosarcoma affects about 400 children and teens in the U.S. every year, representing a small but significant unmet medical need that has seen little therapeutic improvement in decades. Pediatric osteosarcoma is considered a rare disease and may qualify for regulatory incentives including, but not limited to, orphan drug designation, patent term extension, market exclusivity, and development grants. Given the limited availability of new treatment options for pediatric osteosarcoma, and that it is an unmet medical need affecting a very small number of patients in the U.S. annually, the company believes that, subject to regulatory approval, the potential to be on the market may be accelerated.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
09:24 EDTADXSOn The Fly: Pre-market Movers
HIGHER: Caesars Entertainment (CZR), up 23.8% following agreement to merge with Caesars Acquisition (CACQ)... Synthetic Biologics (SYN), up 8.6% following positive topline results from SYN-004 Phase 1a trial... Advaxis (ADXS), up 6.1% after Adage Capital Partners reports 18.84% passive stake in Advaxis... TASER (TASR), up 4.25% following multiple orders of Smart Weapons and Conducted Electrical Weapons... BioCryst Pharmaceuticals (BCRX), up 3.4% after RAPIVAB receives FDA approval... Herbalife (HLF), up 1.4% following a New York Post report that the FDA asked the company to stop airing a video claiming FDA approval. LOWER: Ocwen Financial (OCN), down 10.5% following settlement agreement with New York Department of Financial Services. NOTABLE: Enanta Pharmaceuticals (ENTA), up 11.8% following FDA approval of AbbVie's Viekira Pak... AbbVie is (ABBV) is up 2.4% following FDA approval of Viekira Pak and that Express Scripts (ESRX) will expand access to Viekira Pak... Express Scripts is trading marginally higher... Gilead Sciences (GILD), down 11.3% after Express Scripts picks AbbVie for hepatitis C.
December 19, 2014
16:26 EDTADXSAdage Capital Partners reports 18.84% passive stake in Advaxis
Subscribe for More Information
December 15, 2014
07:33 EDTADXSAdvaxis announces FDA acceptance of INDA to commence clinical trials of ADXS-HPV
Subscribe for More Information
December 8, 2014
09:20 EDTADXSOn The Fly: Pre-market Movers
Subscribe for More Information
07:35 EDTADXSAdvaxis reports FDA acceptance of IND application for ADXS-PSA combination trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use